The COVID-19 outbreak provides India’s pharmaceutical industry a big opportunity, but responsibility as well. India is poised to be a key destination for manufacturing alternatives as the world looks to diversify the global supply chain away from China.
|Number of pages||3|
|Specialist publication||Australian Journal of International Affairs|
|Publisher||Australian Institute of International Affairs|
|Publication status||Published - 21 May 2020|